非小细胞肺癌组织SLC22A18表达与耐药相关性研究  

Expression of SLC22A18 in NSCLC and its correlation with chemoresistance of NSCLC

作　　者：雷鸣[1] 程庆书[2] 李小飞[2] 黄倩[3] 张志培[2] 

机构地区：[1]解放军第三二三医院心胸外科,陕西西安710054 [2]第四军医大学唐都医院胸腔外科,陕西西安710038 [3]解放军第三二三医院内分泌科,陕西西安710054

出　　处：《中华肿瘤防治杂志》2014年第5期368-371,共4页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中SLC22A18的表达与组织学类型、病理分级的关系,以及与相应癌组织对化疗药物敏感性的相关性。方法:应用免疫组化EnVinsion法,检测第四军医大学唐都医院胸外科2005-10-1-2006-06-30手术切除96例NSCLC组织中SLC22A18表达;MTT法检测相应96例癌组织对9种化疗药物的敏感性,分析其与SLC22A18表达的相关性。结果:SLC22A18主要定位于胞膜上和胞质中。在鳞癌、腺癌组织中阳性率分别为68.0%(34/50)和78.2%(36/46),差异有统计学意义,P=0.015。鳞癌Ⅱ、Ⅲ级组织阳性率分别为54.2%(13/24)和80.8%(21/26),差异有统计学意义,P=0.041。腺癌中分化、低分化阳性率分别为69.6%(16/23)和86.9%(20/23),差异有统计学意义,P=0.007。NSCLC组织SLC22A18的表达与其相应组织药物敏感性试验做两因素方差分析,其中环磷酰胺、5-FU、紫杉醇、长春瑞滨、多西他赛和卡铂的P值分别为0.002、<0.001、0.005、0.043、0.001和0.028。结论:SLC22A18在NSCLC组织中高表达,在腺癌中的表达率高于鳞癌,分化越差,表达越高;NSCLC组织中SLC22A18的表达对组织耐药性的产生发挥作用。OBJECTIVE：To investigate the expression of SLC22A18 protein in non-small cell lung cancer（NSCLC） and an- alyze relationship of SLC22A18 expression in these cancer with different histological types and pathological grades;test the chemo- sensitivities, and explore the correlation of the chemosensitivities with SLC22A18 expression in NSCLC. METHODS： The expres- sion of SLC22A18 was detected by immunohistochemistry in 96 cases of NSCLC from October 1st, 2005 to June 30th, 2006 in Tangdu Hospital. The chemoresistance of the same cases was assayed by the MTT method, and the correlation of the chemoresis- tance with expression of SLC22A18 in NSCLC was analyzed statistically. Statistics analysis was carried out with SPSS 17.0 statis- tics software. RESULTS： SLC22A18 was mainly located in cell membrane and cytoplasm. The positive rates in squamous cell lung cancer and lung adenoeareinoma were 68.0% （34/50） and 78.2 % （36/46, P=0. 015）. In squamous cell lung cancer, the positive rates of pathological grade 11 and 111 were 54.2 % （13/24） and 80.8 % （21/26, P=0. 041）. The positive rates of moderately and low differentiated lung adenocarcinoma were 69.6 % （16/23） and 86.9 G （20/23,P= 0. 007）. The two factor analysis of variance among the chemosensitivities of 9 drugs with SLC22A18 expression in NSCLC found that the P values of cyclophosphamide, 5-FU,paclitaxel, vinorelbine, docetaxel, carboplatin were 0. 002, 〈0. 001,0. 005,0. 043,0. 001,0. 028. CONCLUSIONS： The SLC22A18 protein is overexpressed in NSCLC, and the expression of SLC22A18 protein is correlated with histological types and pathological grades. The chemoresistance in NSCLC is correlated with the SLC22A18 expression.

关 键 词：非小细胞肺癌 SLC22A18 多药耐药 药物敏感性 

分 类 号：R734.2[医药卫生—肿瘤]